🟢 Opus Genetics is trading 10.14% up in pre-market after all five low-dose participants reportedly improved vision

Opus Genetics is trading 10.14% up now at $4.78 after positive interim Phase 1/2 BIRD-1 data for OPGx-BEST1.

• All five low-dose cohort participants reportedly showed clinically meaningful vision improvement with a favorable safety profile.
• The company scheduled its topline data presentation for 8:00 a.m. ET on September 9, 2026, making the encouraging clinical update the clear pre-market catalyst.
• Shares closed at $4.34 on September 8 after several recent gains.